Organizational Resources

Websites 

American Association for the Study of Liver Diseases (AASLD) 

Studies and References

Epidemiology

Global Prevalence of MASLD and MASH; Younossi ZM et al. J Hepatol. 2019;71(4):793-801. Quek J et al. Lancet Gastroenterol Hepatol. 2023;8(1):20-30.

MASLD is a Public Health Problem; Le P, et al. Jama Netw Open. 2025;8(1):e2454707
 

Co-morbidities

MASLD is Associated with Increased Risk of Incident Comorbid Conditions; Targher G, et al. Lancet Gastroenterol Hepatol. 2021;6(7):578-588.
 

Liver fibrosis - most important predictor of poor outcomes in patients with MASH

Liver Fibrosis is the Most Important Predictor of Poor Outcomes in Patients with MASH; Sanyal AJ, et al. NEJM. 2021;385(17):1559-1569.

Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort; Simon TG et al. Gut. 2022 Sep;71(9):1867-1875.

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease; Angulo P et al. Gastroenterology. 2015 Aug;149(2):389-97.e10
 

Clinical Practice Guidelines and Goals of Managing MASH

AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease; AASLD Practice Guidance Hepatology. 2023 May 1;77(5):1797-1835.

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings; AACE Clinical guidelines. Endocr Pract. 2022 May;28(5):528-562 7-1835.